Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 24, 2017. The document serves as a transaction notification regarding insider trading activities rather than a financial performance report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It solely reports on specific share transactions involving American Depositary Shares (ADSs).
- Instrument: GlaxoSmithKline plc ADSs (ISIN: US37733W1053)
- Transaction Price: $38.92 per ADS
- Total Volume Reported: 40 ADSs (30 for Dr. M M Slaoui; 10 for Dr. K Slaoui)
Material Changes
No material changes to the company's financial position or operations are reported. The filing details an increase in notional interest in ADSs for two individuals due to the revaluation of the cash element of their notional investment within the GSK 401(K) plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a mandatory disclosure of transactions conducted on January 23, 2017.
Key Facts for Investor Verification
- Transaction Nature: The reported increase in holdings was not a direct market purchase but an allocation resulting from the revaluation of a 401(K) plan cash element.
- Parties Involved: Dr. M M Slaoui (Chairman, Global Vaccines) and Dr. K Slaoui (Person Closely Associated).
- Timing: Transactions occurred on January 23, 2017, and were reported on January 24, 2017.
- Scope: This filing does not contain quarterly or annual financial results.